Liquidia and United Therapeutics resolved their patent dispute with Liquidia agreeing to pay $380.7 million, leading to a 42.6% rise in Liquidia's stock. The settlement ends multiple lawsuits and forces Liquidia to remove a use indication from its drug YUTREPIA, limiting its market to pulmonary arterial hypertension (PAH) patients only. Despite the large payout, investors favored the certainty over the risk of YUTREPIA being pulled from the market entirely. United Therapeutics' shares saw little change, reflecting market expectations. Liquidia's future depends on maintaining or growing sales of YUTREPIA within the reduced market scope and managing cash flow through 2027 without new financing.
Liquidia's stock surged 25.51% on Pluang as of Oct 14, 2026 22:21 WIB, trading at USD 33.65 with a market cap of $2.40 billion. This strong performance follows the resolution of its patent dispute with United Therapeutics, which the news highlights as a key event. Despite the settlement limiting YUTREPIA's market, investors appear to value the reduced legal risk and clearer business outlook.
